Bextra
Valdecoxib skin reactions show distinct pattern
Monday, July 02, 2007
Certain cutaneous adverse reactions to valdecoxib (Bextra) are distinct from Stevens-Johnson...
US FDA chief: Agency open to new pain drugs
Friday, April 13, 2007
The U.S. Food and Drug Administration is still open to new Cox-2 pain drugs, the head of the agency...
Alert: The popular painkiller Bextra (Valdecoxib), used by millions of Americans to relieve symptoms of acute arthritis and painful menstrual cycles, may double the risk of heart deaths, heart attacks and strokes. On April 7, the Food and Drug Administration requested that Pfizer suspend sales of Bextra in the United States due to the increased risks of severe coronary events and the increased risks of Stevens Johnson Syndrome, a potentially fatal skin reaction.
The prescription painkiller Bextra (Valdecoxib) has now been shown to more than double a patient's chance of a severe coronary event such as a heart attack, stroke or some instances, death. This represents a potential risk factor even greater than the painkiller Vioxx, which was removed from the market in September 2004.
Although Bextra's manufacturer Pfizer claimed that Bextra was chemically different than Vioxx and did not present the same heart-related risks, Dr. Garret FitzGerald, a cardiologist and pharmacologist at the University of Pennsylvania, presented data in November proving that patients taking Bextra have a 2.19 times greater risk of experiencing a severe coronary event such as a heart attack, stroke or death. According to Dr. FitzGerald, "The magnitude of the signal with Bextra is even higher than what we saw with Vioxx. This is a time bomb waiting to go off."
Pfizer has also recently warned doctors that Bextra can cause rare but serious skin reactions like Stevens Johnson Syndrome more often than any other drug in its class. These potentially deadly skin reactions occur most often in the first two weeks of Bextra treatment. Bextra now carries a "black box" warning about these skin reaction risks, which is the final warning step before a recall.
If you or a loved one have been injured by Bextra, please call us at
1.800.966.4999
or fill out the form to the right of the page for immediate attention to your case.
Schwartzapfel Partners
With over 150 years of combined experience and highly competent co-counsel throughout the country, we can serve all your legal needs. Schwartzapfel Partners protects the rights of those who aren't able to do so themselves.
Learn More
-- Area of your concern --
Accutane
Aranesp
Bard Composix Pain Patch
Bextra
Celebrex
Celexa
Complete MoisturePlus
Concerta
COX-2 Inhibitors
Crestor
Defective Drug Resources
Desmopressin Acetate
Duragesic Patches
Elidel
Fentanyl Patch
Fentora
Foradil Aerolizer
Fosamax
Hormone Replacement Therapy
Ketek
Methazolamide
Mirapex
NuvaRing
Ortho Evra
Paxil
Permax
Plavix
Procrit
Protopic
Prozac
ReNu Contact Solution
Ritalin
Seroquel
Tamiflu and Relenza
Tequin
Trasylol
Viagra
Vioxx
Zelnorm
Zicam
Zithromax
Zoloft
Zyprexa
Briefly describe your case and resultant injuries...
Gender:
Male
Female
-- Your Age --
1 - 9
9 - 19
20 - 39
40 - 49
50+
-- Symptom --
Heart Attack / Stroke
In what state did the incident occur?
select a state
AL
AK
AZ
AR
CA
CO
CT
DE
DC
FL
GA
HI
ID
IL
IN
IA
KS
KY
LA
ME
MD
MA
MI
MN
MS
MO
MT
NE
NV
NH
NJ
NM
NY
NC
ND
OH
OK
OR
PA
RI
SC
SD
TN
TX
UT
VT
VA
WA
WV
WI
WY
Schwartzapfel Truhowsky Marcus
Sachs P.C.
disclaimer
.
Bextra
What is Bextra?
Coronary Events
Skin Conditions
Bextra's Hidden Risks
What Can I Recover?
Home
Site Map
Terms and Conditions
Schwartzapfel Truhowsky Marcus Sachs P.C. All Rights Reserved.